Evidence map›Paper›PMID 41089760›Full record

ArticleInternational journal of pharmaceutics: X2025

Colistin and Oxyclozanide co-loaded PLGA nano-microspheres to reverse colistin resistance can effectively treat colistin-resistant

Shuai-Hua Li, Meng-Jing Feng, Hao-Tian Shao, Jian-Hua Liu, Hua Wu, Li Yuan, Xiao-Yuan Ma, Gong-Zheng Hu

Abstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuai-Hua LiDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
Meng-Jing FengDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
Hao-Tian ShaoDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
Jian-Hua LiuDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
Hua WuDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
Li YuanDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
Xiao-Yuan MaDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
Gong-Zheng HuDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colistin (COL) is widely recognized as the last line of defense for treating MDR-negative bacterial infections, but currently, bacteria have a very serious resistance to COL. The combination of antibacterial drugs and adjuvant drugs can reverse drug resistance, enhance antibacterial activity, and improve therapeutic effects. It is currently regarded as a new safe and effective strategy for controlling drug resistance. In this study, we found that the combination of Oxyclozanide (OXY) and colistin can effectively reverse colistin resistance. For multiple colistin resistant

Indexed as

ColistinCo-loaded microsphereEscherichia coli infectionOxyclozanideResistance reversal

Identifiers

PMID41089760
PMCPMC12516539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.